SEQUENT

Viyash Scientific share price & financials

Price
₹269.1
Market cap
₹4.8k Cr
Sector
Healthcare

What Viyash Scientific Limited does

SeQuent Scientific is an integrated animal health (veterinary pharmaceutical) company that manufactures Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) for livestock, poultry and companion-animal care, marketed under its Alivira brand. It earns revenue by selling APIs to formulators and pharma companies and by selling branded/generic veterinary formulations (injectables, oral solutions/suspensions, powders, premixes and other dosage forms) to distributors, veterinarians and farmers, with manufacturing spread across India, Europe (Spain), Turkey and Brazil. Sales are split between regulated markets (Europe) and emerging markets (Latin America, India and rest of world). The company is in the process of a strategic merger with Viyash Life Sciences to build a combined, end-to-end animal health platform.

Segments

  • Formulations
  • API
Manufacturing facilities
7 (2 API + 5 formulation) across India, Spain, Turkey and Brazil
Countries served
90+
Product registrations
1,000+ across 12 dosage forms
Employees
1,600+
R&D centres
5, located in India, Spain, Brazil and Turkey
Commercial API portfolio
35
Headquarters Hyderabad, Telangana Company website

Quarterly results

Q1 FY27: revenue up 19.4%, net profit up 113.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue369 774 402 792 850 +130%858 +11%920 +129%946 +19%
EBITDA39 100 46 119 173 +344%176 +76%184 +300%178 +50%
Net profit6 42 10 37 73 +1117%49 +17%66 +560%79 +114%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +40.3% 1Y

₹200₹250₹300Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹183.17 on 10 Sept 2025 → ₹257. High ₹294.2 (3 Jul 2026), low ₹179.9 (23 Mar 2026).

Financials, as filed

Revenue grew 34.0% a year over 3 years, FY23 to FY26. Operating margin widened to 19.1%.

Year endingFY23FY24FY25FY26
Revenue₹1.4k Cr₹1.4k Cr₹1.9k Cr₹3.4k Cr
Operating profit₹12 Cr₹61 Cr₹227 Cr₹652 Cr
Operating margin0.8%4.5%11.7%19.1%
Interest₹36 Cr₹48 Cr₹66 Cr₹70 Cr
Depreciation₹56 Cr₹60 Cr₹107 Cr₹234 Cr
Net profit₹-121 Cr₹-30 Cr₹67 Cr₹225 Cr
Net margin-8.5%-2.2%3.5%6.6%
Cash from operations₹17 Cr₹31 Cr₹345 Cr₹323 Cr
Free cash flow₹-58 Cr₹19 Cr₹258 Cr₹225 Cr
ROCE-3.0%0.0%8.0%13.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹50 Cr₹50 Cr₹50 Cr₹50 Cr₹50 Cr₹87 Cr
Reserves₹678 Cr₹642 Cr₹649 Cr₹607 Cr₹759 Cr₹2.8k Cr
Borrowings₹277 Cr₹365 Cr₹444 Cr₹488 Cr₹490 Cr₹490 Cr
Other liabilities₹381 Cr₹378 Cr₹374 Cr₹389 Cr₹427 Cr₹1.2k Cr
Total liabilities₹1.4k Cr₹1.4k Cr₹1.5k Cr₹1.5k Cr₹1.7k Cr₹4.6k Cr
Fixed assets₹536 Cr₹564 Cr₹605 Cr₹592 Cr₹628 Cr₹2.1k Cr
Capital work in progress₹31 Cr₹12 Cr₹55 Cr₹16 Cr₹5 Cr₹70 Cr
Investments₹83 Cr₹38 Cr₹0 Cr₹4 Cr₹0 Cr₹0 Cr
Other assets₹737 Cr₹821 Cr₹856 Cr₹922 Cr₹1.1k Cr₹2.4k Cr
Total assets₹1.4k Cr₹1.4k Cr₹1.5k Cr₹1.5k Cr₹1.7k Cr₹4.6k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs trimmed −9.22 pp while promoters added +8.70 pp. The shareholder count shrank 13% to 1,28,367.

Promoters
61.3%
FIIs
4.5%
DIIs
3.8%
Public
30.3%
Others
0.1%

Since Jun 2025

  • DIIs −9.22 pp
  • Promoters +8.70 pp
  • Public +2.24 pp

How it drifted, 12 quarters

Over this window promoters went from 52.8% to 61.3% — +8.5 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 52.8%, FIIs 6.0%, DIIs 3.2%, Public 37.6%, Others 0.4%.Dec '23: Promoters 52.8%, FIIs 6.1%, DIIs 7.2%, Public 33.7%, Others 0.2%.Mar '24: Promoters 52.8%, FIIs 6.2%, DIIs 7.6%, Public 33.3%, Others 0.2%.Jun '24: Promoters 52.8%, FIIs 5.7%, DIIs 8.1%, Public 33.3%, Others 0.2%.Sep '24: Promoters 52.8%, FIIs 6.5%, DIIs 10.0%, Public 30.6%, Others 0.2%.Dec '24: Promoters 52.6%, FIIs 6.1%, DIIs 12.0%, Public 29.1%, Others 0.2%.Mar '25: Promoters 52.6%, FIIs 6.0%, DIIs 12.8%, Public 28.4%, Others 0.2%.Jun '25: Promoters 52.6%, FIIs 6.2%, DIIs 13.0%, Public 28.1%, Others 0.2%.Sep '25: Promoters 52.3%, FIIs 5.9%, DIIs 12.9%, Public 28.7%, Others 0.2%.Dec '25: Promoters 61.4%, FIIs 3.2%, DIIs 7.4%, Public 28.0%, Others 0.1%.Mar '26: Promoters 61.3%, FIIs 2.9%, DIIs 8.0%, Public 27.7%, Others 0.1%.Jun '26: Promoters 61.3%, FIIs 4.5%, DIIs 3.8%, Public 30.3%, Others 0.1%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Viyash Scientific Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ca Hull Investments 31.17%unchanged
Ca Harbor Investments 30.14%unchanged
Haribabu Bodepudi 2.77%unchanged
Quant Mutual Fund - Quant Small Cap Fund Mutual fund2.58%newly disclosed
Kalidindi Srihari Raju 2.35%−0.14 pp
Narasimha Reddy Duthala 1.27%unchanged
Quant Mutual Fund - Quant Manufacturing Fund Mutual fund—off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Viyash Scientific Limited

Guides on how to read this kind of business and the numbers that matter.